Circular ribonucleic acids (circRNAs) are widely expressed in human cells and play an important role in the pathogenesis of many diseases. Some circRNAs have microRNA (miRNA) binding response elements and interact with miRNA to regulate the expression of target genes.Four patients with a preliminary diagnosis of dengue fever (DF), peripheral whole blood sample in anticoagulant was collected before treatment (pretreatment group) and after effective treatment (posttreatment group), and eight samples were separated and used to screen differentially expressed circRNAs with microarray analysis. The relative expression level of circRNAs was determined using reverse-transcription polymerase chain reaction (RT-PCR). TargetScan v7.1 and miRDB v5 bioinformatics software were used to predict circRNA-binding miRNAs; dual luciferase reporters were constructed to detect binding between circRNA and miRNA. Microarray screening revealed 263 differentially expressed circRNAs in peripheral leukocytes pretreatment versus posttreatment; 107 of these were upregulated and 156 were downregulated. RT-PCR confirmed that hsa_circ_0015962 was significantly upregulated and hsa_ circ_0006459 significantly downregulated (P < 0.05). Moreover, hsa_circ_0015962 binds to miR-4683, and hsa_circ_0006459 binds to miR-133b.Downregulation of hsa_circ_0006459 and upregulation of hsa_circ_0015962 affect the treatment response of DF and are potential biomarkers in DF patients. The molecular mechanism involves hsa_circ_0006459-mediated targeted negative regulation of miR-133b and hsa_circ_0015962-mediated targeted negative regulation of miR-4683.
day 2 and reaches its nadir (as low as 2 × 10 9 /L) by days 4-5. Moreover, thrombocytopenia occurs in most cases, and platelet count can be as low as <10 × 10 9 /L 6 , with varying degrees of liver and myocardial damage.
The role of circRNA in the pathogenesis and treatment response of DF is unknown. In this study, we collected peripheral blood samples from 43 DF patients pre-and post treatment, analyzed the relative expression of differentially expressed circRNAs, and investigated potential molecular mechanisms, in order to provide a basis for further research on the pathogenesis of DF and related mechanisms of treatment response. 8 . Exclusion criteria were chronic liver disease, diabetes, chronic kidney disease, malignant tumor with metastasis, or hematologic disease. This study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of our hospital. According to the treatment guidelines, patients were placed on bed rest with a light diet and were quarantined in a ward with beds covered with insecticide-treated mosquito nets and other anti-mosquito equipment until more than 5 days after disease onset and body temperature had returned to normal for more than 24 h. Moreover, symptomatic and supportive care was given, and measures were taken to prevent and treat various complications Isolation of leukocytes. Fresh venous blood was drawn and leukocytes were isolated within 6 h after blood collection to ensure their survival. Density gradient centrifugation was employed for leukocyte isolation at 18-20 °C using Red Blood Cell Lysis Buffer (Solarbio, Beijing, China), according to the manufacturer's instructions.
Methods
Total RNA extraction from leukocytes and circRNA microarray analysis. Peripheral blood leukocytes were collected pre-and post-treatment from DF patients to extract total RNA using TRIzol reagent (Thermo Fischer Scientific, Waltham, MA) according to the manufacturer's instructions. RNA samples were sent to KANGCHEN Inc. (Shanghai, China) for Arraystar circRNA Microarray analysis. The Human 8 × 15 K cir-cRNA Array, which contains 9114 circRNA probes, is manufactured by Arraystar Technologies (Rockville, MD). Each circRNA was identified by using a specific probe that targets the specific splice junction of circRNA. Sample labeling and array hybridization were performed according to the manufacturer's protocol (Arraystar). R software package (version 3.1.2) was used for normalizing the raw data and for subsequent data processing. Two groups of profile differences (pretreatment samples versus posttreatment samples), and the absolute fold change for each circRNA was computed 9 . The predicted interaction between circRNAs/miRNAs predicted use the targetscan and miRanda software.
RT-PCR assays of significant differentially expressed circRNAs. RNA Luciferase reporter assay. Genomic DNA was extracted from peripheral blood cells and used as a template for the linear sequence of circRNA, and XhoI and NotI restriction sites were introduced. The PCR amplification product was subjected to double digestion with the respective enzymes and cloned into the psiCHECK-2 vector. The ligated products were then transformed into Escherichia coli DH5a cells. A blue/white screening assay and 
Results
Clinical data of subjects. In this study, Dengue fever patient were divided into two groups based on their T-scores for hematological indices, and these differed significantly between the two groups ( Table 3) . Mean values for total and differential WBC count, red blood cell count, hemoglobin, hematocrit, mean corpuscular hemoglobin, platelet count (PLT), plateletcrit, and the glucose, alanine transaminase, total bile acids, and electrolyte levels are also shown. There were significant differences between the pretreatment and post treatment groups as shown in Table 3 .
CircRNA expression profiles.
In total, 10958 circRNAs were analyzed by circRNA microarray in four pairs of pretreatment and posttreatment samples from patients with a preliminary diagnosis Dengue fever. Fold changes (FC) of circRNA expression in both groups were measured to identify differentially expressed circRNAs ( Fig. 1A ). Volcano plots identified substantial changes in the levels of 263 circRNAs (FC ≥ 1.5), including 107 upregulated and 156 downregulated circRNAs(Supplementary File 1); this was statistically significant (P < 0.05; Fig. 1B -D). Four circRNAs were selected based on the FC of differential expression and initial expression level, including 2 upregulated circRNA and 2 downregulated circRNA (Table 4) ,We have performed GO and KEGG analyses(Supplementary Files 2, 3). Two circRNAs with the most change in expression were selected for sequence analysis and the potential miRNA targets of these circRNAs were predicted accordingly ( Fig. 2A,B ).
RT-PCR assay for significantly differentially expressed circRNAs and interaction between targeting miRNA.
We performed RT-PCR (pre-treatment, n = 43; post-treatment, n = 43). Trends for the 2 circRNAs were consistent with the results of microarray analysis. The results indicated that the expression of hsa_circ_0015962 was higher in the posttreatment group than pretreatment group (Fig. 3A ). hsa_circ_0006459 expression was lower in the posttreatment group than in the pretreatment group (Fig. 3B ). Also, while expression of miR-4683 was lower, miR-133b expression was higher in the posttreatment group than in the pretreatment group. We could not detect the expression of miR-4692, miR-4802-3p, miR-7161-3p, miR-6893-5p, miR-598-5p, miR-301a-5p, miR-92a-2-5p, and miR-133a-3p in the posttreatment samples ( Fig. 3C) . To investigate the regulatory mechanisms of hsa_circ_0015962 and hsa_ circ_0006459 expression, we constructed wild-type and mutant hsa_circ_0015962 and hsa_circ_0006459 vectors, which were respectively co-transfected with miR-133b and miR-4683 mimics into 293T cells. Luciferase activity was detected, and showed that hsa_circ_0015962 binds to miR-4683, and hsa_circ_0006459 binds to miR-133b ( Fig. 3D,E) . Taken together, these results indicate that hsa_circ_0006459 targets and negatively regulates miR-133b expression, and hsa_circ_0015962 targets and negatively regulates miR-4683 expression.
Correlation of clinical variables with hsa_circ_0015962 and hsa_circ_0006459 in PBMCs from post-treatment samples.
In order to evaluate the correlation between circRNAs differentially expressed in PBMC S of peripheral blood of patients with dengue fever and biological indicators, we analyzed for the Pearson correlation coefficient to assess the correlation between post-treatment clinical data and hsa_circ_0015962, hsa_ circ_0006459 ( Table 5 ). The results showed that hsa_circ_0006459 was negatively correlated with WBC, PLT and differential lymphocyte count (r = −0.259, r = −0.356, r = −0.203; P < 0.05). The levels of hsa_circ_0015962 in PBMCs from post-treatment samples positively correlated with WBC, PLT, and differential lymphocyte count (r = 0.562, r = 0.789, r = 0.35, P < 0.05). Table 2 . Primer for miRNA.
Discussion
In our study, we aimed to identify a potential prognostic biomarker in PBMCs of patients with DF. The results showed that hsa_circ_0015962 expression was significantly increased in DF patients, and hsa_circ_0006459 was significantly decreased in DF patients, and therefore can serve as potential prognostic biomarkers for Dengue fever patients. With the development and maturity of high-throughput sequencing technology, more and more circRNAs have been discovered and named, and their biological characteristics, formation mechanism and action Table 3 . Clinical results of Dengue fever patients in both groups. Note: The data above are expressed as the mean ± standard deviation.
mechanism have been revealed gradually 11 . Different from the traditional linear RNA, circRNAs are closed-loop and not easily degraded by nucleic acid exonuclease RNaseR, so they have good stability 12 . Therefore, circRNA can be a potential diagnostic and prognostic biomarker. Hsa_circRNA_103571 may serve as a potential biomarker for diagnosis of active tuberculosis (TB), and hsa_circRNA_103571-miRNA-mRNA interaction may be a novel mechanism in active TB 13 . Gastric Adenocarcinoma-Associated, Positive CD44 Regulator. The intergenic lncRNA GAPLINC may promote primary hepatocellular carcinoma (PHCC) progression and serve as a potential prognostic marker and therapeutic target in PHCC 14 . Salivary circRNAs hsa_circ_0001874 and hsa_ circ_0001971 were reported as novel biomarkers for the diagnosis of oral squamous cell carcinoma 15 . In addition, hsa_circ_0074362 probably plays a role in the initiation of gastric cancer and may be a potential biomarker of gastric cancer 16 . Also, hsa_circ_0001785 showed higher expression in peripheral blood of breast cancer patients, and thus could be a stable biomarker for diagnosis and disease progression 17 . The detection of cireRNA mainly focuses on tissue samples. This method is traumatic and not suitable for early clinical diagnosis of tumors. Clinical samples, such as serum, urine and body fluids, are much easier than tissue samples.The expression of circRNA in serum and disease-related body fluids (gastric juice, cerebrospinal fluid, serous effusion, etc.) should be further studied in the future 9 . The characteristics of circRNA (universality, conservativeness, tissue-cell specificity and stability) also suggest that It may be superior to linear RNA in the detection of clinical samples. High diagnostic value 9 . Upon infection, the virus first proliferates in the capillary endothelial cells and is then released into the bloodstream. The resulting viremia leads to further infection of mononuclear macrophages in the bloodstream and tissues and ultimately causes DF 18 . Leukopenia, especially neutropenia, is the primary laboratory finding; and thrombocytopenia occurs in most cases 6 . In our study, we found that hsa_circ_0006459 was negatively correlated with WBC, PLT, and lymphocyte count. hsa_circ_0015962 levels in PBMCs from post-treatment samples positively correlated with WBC, PLT, and lymphocyte counts. These observations may facilitate future pathophysiological research on treatment response of DF and help to determine whether circRNAs in PBMCs could be used as novel, non-invasive biomarkers for diagnosis and prognosis of patients with DF.
CircRNA plays an important role in various diseases,CircRNA can be used as microRNA sponge, RBP sponge or direct binding Target RNA regulates the expression of RNA 19, 20 . In this study, we found that the expression of hsa_circ_0015962 and miR-133b was higher in the posttreatment group than pretreatment group. Expression of hsa_circ_0006459 and miR-4683 was lower in the posttreatment group than in the pretreatment group. Moreover, that hsa_circ_0015962 binds to miR-4683, and hsa_circ_0006459 binds to miR-133b.This study shows that hsa_ circ_0006459 targets and negatively regulates miR-133b expression and hsa_circ_0015962 targets and negatively regulates miR-4683 expression, and this provides a new direction for research on the pathological mechanism of treatment response of DF. CircFUT10 regulates myocardial proliferation and differentiation by competitively binding to miR-133a 21 . circHECW2 competitively sponges miR-30D and upregulates ATG5, thereby promoting transformation of cerebral microvascular endothelial cells into stromal cells and consequent damage to the blood-brain barrier 22 . Renal miR-150 showed a tendency to negative correlation with circHLA-C in patients with lupus nephritis. Thus, circHLA-C may play an important role in the pathogenesis of lupus nephritis by sponging miR-150 23 .
There are some limitations in our study. First, dengue fever is a seasonal disease, fewer cases have been collected. Second, we did not confirm the binding between hsa_circ_0015962 and miR-4683 or between hsa_ circ_0006459 and miR-133b with RNA pull-down assay. Third, We did not analyze the expression of circRNAs in plasma, serum, saliva and exosomes of patients. Studies have shown that the expression of cirRNA in exosomes is more stably than that in body fluids, and has higher diagnostic value 24 .
In our further study, we will explore the limitations in this study. To the best of our knowledge, this is the first study that used circRNA microarray to determine the expression of circRNA in PBMCs of pre-and Table 4 . Differential expression circRNA peripheral blood leucocyte was screened by CircRNA microarry Table 5 . Pearson correlation coefficient was used to analyze the correlation between hsa_circ_0015962, hsa_ circ_0006459 and clinical related variables. * P < 0.05, ** p < 0.01.
